

Minutes of the **Somerset Prescribing Forum** held in **Meeting Room 2, Wynford House, Luffton Way, Yeovil, Somerset** on **Wednesday 14th March 2018**

Present:	Dr Clare Barlow (CB)	Chair, Drug & Therapeutics Committee, Taunton & Somerset NHS FT
	Jon Beard (JB)	Chief Pharmacist, Taunton & Somerset NHS FT
	Steve Du Bois (SDB)	Chief Pharmacist- Head of Medicines Management, Somerset Partnership NHS Foundation Trust
	Shaun Green (SG)	Associate Director, Head of Medicines Management, NHS Somerset CCG
	Catherine Henley (CH)	Medicines Manager, NHS Somerset CCG
	Andrew Prowse (AP)	Chief Pharmacist, Yeovil District Hospital
	Dr Geoff Sharp (GS)	GP Delegate (Central Mendip Commissioning Locality), Chair
	Zoe Talbot-White (ZTW)	Prescribing Support Technician, NHS Somerset CCG
Apologies:	Sam Morris (SJM)	Medicines Manager, NHS Somerset CCG
	Jean Perry (JP)	Commissioning Manager, NHS Somerset CCG

1 INTRODUCTIONS

GS welcomed members to the meeting and introduced Andrew Prowse, the new Chief Pharmacist at YDH to the group.

2 APOLOGIES

Apologies were given, as detailed above.

3 DECLARATIONS of INTEREST

SDB took part in a Sanofi sponsored event, around 'risk sharing between the pharmaceutical industry and the NHS and his honorarium for this was paid to SomPar. DOIs to be updated.

Action: ZTW

SPF needs to provide a DOI proforma to Andrew Prowse and DOIs need to be updated.

Action: ZTW

4 MINUTES OF THE MEETING HELD ON 17th January 2018

4.1 Agreed as an accurate record of the meeting.

4.2 Review of action points:

Most items were either complete or on the agenda. The following points were specifically noted:

Action point 5: CH to approach Simon Davies to align the YDH and TST LMWH bridging policies.

Action: CH

Action point 6: Falsified Medicines directive implementation; AP updated the group that YDH is waiting on a national Steer; JB said that they are starting to work on it and that their dispensing system will eventually be compliant.

5 MATTERS ARISING

5.1 An audit on Antipsychotic prescribing in people with learning disabilities

SDB reported that here were some gaps in the SomPar data and they are looking to undertake some secondary analysis.

5.2 Draft Single Shared Care Guideline for DMARDs and monitoring

CH discussed the main changes to the document:

- The name of the shared care guide has been changed from Disease modifying anti-rheumatic drugs to Immunomodulatory therapies in rheumatology/gastroenterology and dermatology conditions.
- Updates around pregnancy and lactation from the new BSR guidance.
- Added: avoid concomitant administration of other xanthine oxidase inhibitors to Azathioprine and Mercaptopurine.
- Hydroxychloroquine maximum dose has been reduced due to the risk of retinopathy. The Royal College of ophthalmology has just published guidance around Hydroxychloroquine.
- Sally Knight has confirmed the changes that need to be made with Leflunomide with pregnancy and lactation.
- The format has been changed to make the document more easily readable.

SPF discussed the retinopathy risk with hydroxychloroquine as RCO have recommend a baseline eye exam and regular follow ups, especially for patients having five or more years of therapy. Implementation of the guidance needs to be considered and decided by the commissioners.

There are already issues with ophthalmology follow ups. The group were unsure if the follow up needs to be done by an ophthalmologist or if patients could be seen by optometrists in primary care. Historically GPs should recommend patients visit the optometrist every year for a check-up.

RuH have raised concerns about the number of patients this will involve and the increased pressures.

SG has already asked JP to raise with the LOC.

Trusts to consider and bring back to May SPF.

Action: JB & AP

It was suggested at PAMM that on page 15 'For patient starting treatment:' could be changed to 'For patient starting treatment, standard monitoring:', SPF agreed this would be appropriate Make the change to the document.

Action: CH

Re-send the RCO documents to SPF members.

Action: ZTW

5.3 Anticoagulant Bridging Protocol for Patients Undergoing Elective or Planned Procedures

This was discussed during review of the action points (action point 5).

5.4 UKMI- Heparin based flushing solutions

SG brought this because of the cannula flushing safety alert discussed at SPF in January.

TST largely use saline and occasionally use heparin for a central line. AP will check at YDH but thinks it would be mainly saline used.

6 OTHER ISSUES

6.1 Follow up from coroner Regulation 28 report to prevent future deaths: Benzodiazepines and suicide

A national letter to raise awareness of deaths occurring due to withdrawal of Benzodiazepines.

Primary care will have to opportunity to carry out a hypnotics audit and this could form part of the audit. Ideally patients won't be on them long term but we need to be aware of the risks of reducing.

There have been a number of complaints to the CCG over the years about patients that have become addicted to benzodiazepines and not been able to stop.

TST have a policy and do not attempt to withdraw.

SDB informed the group that online purchasing is an issue.

6.2 The Report of the Short Life Working Group on reducing medication-related harm

Recommendations on medication-related harm viewed.

Most recommendations are already being implemented.

TST are planning to switch to a new stock control and labelling system.

Eclipse live is being used in preference of PINCER.

6.3 Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

SomPar have previously reviewed the use of Agomelatin and it wasn't recommended.

Due to this meta-analysis SomPar will take Agomelatin to the next DTC with more evidence for prescribing. They may bring back to a future PAMM with an application for addition to the formulary.

-Noted

6.4 RMO function on SPS website

The regional medicines optimisation committee now have a section on the SPS website so we can note what they are producing.

SG fed back to Steve that the TOR states members should take sounding and views from their peers. Steve will raise nationally.

Add to the agenda as a standing item.

Action: ZTW

6.5 Responsibility for prescribing between Primary & Secondary/Tertiary care

This revised guidance will now start to be referenced in our Shared Care Guidance when being reviewed. Use as a reference document for shared care discussions going forward.

-Noted

7 Formulary Applications

7.1 Enoxaparin Becat[®] solution for injection pre-filled syringe (ROVI Biotech Limited)

SG recommended that Enoxaparin is now prescribed by brand from a safety aspect so patients don't get switched in community pharmacy. JB and AP will raise internally but cannot guarantee brand prescribing.

Not recommended for a switch and will be guided by secondary care choice.

-Approved

Add to formulary and TLS **GREEN**, recommended brand prescribing.

Action: ZTW & Steve Moore

- 7.2 Esmya (ulipristal acetate) – proposed change of traffic light status to **RED**
 This was part of the pathway for endometriosis but has since been removed due to the MHRA alert.
 Agreed to make a **RED** drug.
 Change TLS to **RED**. **Action: ZTW & Steve Moore**
- 8 **DTC decisions and other reports**
- 8.1 **Somerset Partnership Mental Health D&TC – Last meeting 13/03/18**
 SomPar confirmed that they don't advocate pro-biotics or herbal medications unless they have been approved by PAMM and are on the Somerset prescribing formulary or traffic lights.
 A decision was made to have one shared care guideline for all antipsychotics to cut admin.
 SomPar are trialling an inhaled antipsychotic for use in de-escalation in in-patients.
- 8.2 **YDH D&TC – Has been replaced by Medicines Committee meetings. Next meeting 28/03/18**
- 8.3 **T&ST D&TC – Last meetings 10/11/17, 9/02/18- Nov minutes received**
 New drug request for inhaled methoxyflurane for trauma patients is being considered, waiting for cost saving information.
 Updated chemotherapy anti-emetic guidance, due to ASCO guidance changes. Share guidance with AP. **Action: CB**
 Akynzeo was approved for prevention of acute and delayed N&V.
 Add to TLS **RED**. **Action: ZTW & Steve Moore**
 Report of lidocaine patches use will be discussed in May.
- 8.4 **T&S Antimicrobial Prescribing Group – Last meeting 14/02/18 – Minutes not received**
- 8.5 **RUH Bath D&TC – Last meetings 14/12/17, 11/01/18, 08/02/18, 08/03/18 – Dec & Jan & Feb minutes received**
 Nothing to note
- 8.6 **BNSSG D&TC — Last meeting 24/01/18 – Minutes received**
 Noted the low value medicines consultation results from NHSE. They noted that Weston have a liothyronine protocol and will only be used in extenuating circumstances and will now be a **RED** drug.
 Somerset CCG has the lowest use of liothyronine in the country.
- 8.7 **BNSSG Joint Formulary Group – Last meeting 16/01/18 – Minutes received**
 Nothing to note
- 8.8 **LPC report**
 Nothing to note
Part 2 – Items for Information or Noting
- 9 **NICE Guidance**
- NICE Technology Appraisals**
- 9.1 TA498 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
 Noted. Positive appraisal. Specialist commissioning NHSE funded.
 TLS **RED** drug. **Action: Steve Moore & ZTW**
- 9.2 TA499 Glecaprevir–pibrentasvir for treating chronic hepatitis C
 Noted. Positive appraisal. Specialist commissioning NHSE funded.
 TLS **RED** drug. **Action: Steve Moore & ZTW**

- 9.3 TA500 Ceritinib for untreated ALK-positive non-small-cell lung cancer
Noted. Positive appraisal. Specialist commissioning NHSE funded.
TLS **RED** drug. **Action: Steve Moore & ZTW**
- 9.4 TA501 Intrabeam radiotherapy system for adjuvant treatment of early breast cancer
Noted. Not recommended
- 9.5 TA502 Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Noted. Positive appraisal. Specialist commissioning NHSE funded.
TLS **RED** drug. **Action: Steve Moore & ZTW**
- 9.6 TA503 Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Noted. Not recommended
TLS **BLACK** drug. **Action: Steve Moore & ZTW**
- 9.7 TA504 Pirfenidone for treating idiopathic pulmonary fibrosis
Noted. Positive appraisal. Specialist commissioning NHSE funded.
TLS **RED** drug. **Action: Steve Moore & ZTW**
- 9.8 TA505 Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Noted. Positive appraisal. Specialist commissioning NHSE funded.
TLS **RED** drug. **Action: Steve Moore & ZTW**
- 9.9 TA506 Lesinurad for treating chronic hyperuricaemia in people with gout
Noted. Not recommended
TLS **BLACK** drug. **Action: Steve Moore & ZTW**
- 9.10 TA507 Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Noted. Positive appraisal. Specialist commissioning NHSE funded.
TLS **RED** drug. **Action: Steve Moore & ZTW**
- 9.11 TA508 Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee
Noted. Positive appraisal.
- 9.12 TA509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Noted. Positive appraisal. Specialist commissioning NHSE funded.
TLS **RED** drug. **Action: Steve Moore & ZTW**
- 9.13 TA160 Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women -Update
Update the title and guidance have been updated to reflect the current recommendations. Guidance on strontium ranelate and etidronate have been removed because these drugs are no longer marketed in the UK.
-Noted

- 9.14** TA161 Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women -Update
Update the title and guidance (section 1) have been updated to reflect the current recommendations. Guidance on strontium ranelate and etidronate have been removed because these drugs are no longer marketed in the UK.
-Noted
- 9.15** TA464 Bisphosphonates for treating osteoporosis -Update
Update this guidance partially updates NICE TA guidance on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160) and on raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161).
-Noted
- 9.16** [MTG36] Peristeen transanal irrigation system for managing bowel dysfunction
NICE recommends Peristeen (Coloplast) for transanal irrigation in people with bowel dysfunction. It has been shown to reduce severity of constipation and incontinence, improve quality of life and promote dignity and independence.
-Noted
Peristeen is being recommended by GI nurse teams. SG has asked if a pathway and a business plan can be put together for the patients that will benefit from using this product. Nothing is agreed at the moment. Currently there are no committees within Trusts to make formulary decisions about appliances.
Raise document internally and put forward patient groups the product may benefit.
Action: JB and AP
- 10 NICE Clinical Guidance**
- 10.1** NICE Guidance and advice list updates
-Noted
- 10.2** NG82 Age-related macular degeneration -New
-Noted
Agreed position in line with TAGs
- 10.3** NG83 Oesophago-gastric cancer: assessment and management in adults -New
-Noted
- 10.4** NG84 Sore throat (acute): antimicrobial prescribing -New
-Noted
Antimicrobial guidance has been updated according to this guidance.
- 10.5** NG85 Pancreatic cancer in adults: diagnosis and management -New
-Noted
- 10.6** NG86 People's experience in adult social care services: improving the experience of care and support for people using adult social care services -New
-Noted

- 10.7** CG147 Peripheral arterial disease: diagnosis and management -Update
-Noted
Identify any specific drug changes. **Action: CH**
- 11** **Specialist Commissioning**
11.1 None this month
- 12** **PBR excluded drug monitoring**
12.1 **T & S**
Send JB and Peter Fry a copy of YDH format for reporting high cost drug data.
Action: CH
- 12.2** **Yeovil**
Look into why there have been some increases in costs. **Action: AP**
- 13** **Horizon Scanning**
13.1 NICE forward planner
-Noted
- 14** **Safety items, NPSA Alerts and Signals**
14.1 **MHRA February & March Drug Safety Update**
-Noted
- 15** **BNF Changes**
BNF Update January and February
-Noted
- 16** **Any other business**
16.1 Somerset Prescribing Formulary for Primary and secondary care
AP would like one formulary website for Somerset CCG and Trusts.
SG told the group that it would involve a lot of work to update the CCG website to include all of the core drugs and it wouldn't be something the CCG would take on.
YDH to look at TST BNF based formulary. **Action: AP**
- 16.2** **Sepsis lead in primary care**
SG highlighted the recommendation that every practice has a sepsis lead.
Noted at PAMM.

Date of Next Meetings:

Wednesday 23rd May 2018
Wednesday 18th July 2018
Wednesday 19th September 2018
Wednesday 21st November 2018

SOMERSET PRESCRIBING FORUM
SCHEDULE OF ACTIONS ARISING FROM THE MEETING HELD ON 14th March 2018

NO.	SUBJECT	OUTSTANDING RESPONSIBILITY	ACTION LEAD	Status
1	Declarations of interest (1)	Members were asked to notify the Prescribing Forum secretary of any standing declarations of interest, which should be held on record.	All (on going)	Ongoing
2	Declarations of interest	<ul style="list-style-type: none"> • SDB took part in a Sanofi sponsored event, around 'risk sharing between the pharmaceutical industry and the NHS and his honorarium for this was paid to SomPar. • SPF needs to provide a DOI proforma to Andrew Prowse • DOIs need to be updated. 	Zoe Talbot-White 23rd May 2018	
3	Anticoagulant Bridging Protocol	Approach Simon Davies to align the YDH and TST LMWH bridging policies.	Catherine Henley 23rd May 2018	
4	Draft Single Shared Care Guideline for DMARDs and monitoring	<ul style="list-style-type: none"> • Trusts to consider and bring back to May SPF. • It was suggested at PAMM that on page 15 'For patient starting treatment:' could be changed to 'For patient starting treatment, standard monitoring:', SPF agreed this would be appropriate Make the change to the document. • Re-send the RCO documents to SPF members. 	Jon Beard & Andrew Prowse Catherine Henley Zoe Talbot-White 23rd May 2018	
5	RMOC function on SPS website	Add to the agenda as a standing item.	Zoe Talbot-White 23rd May 2018	Complete
6	Chemotherapy anti-emetic guidance	Share guidance with AP.	Clare Barlow 23rd May 2018	
7	Peristeen transanal irrigation system	Raise document internally and put forward patient groups the product may benefit.	Jon Beard & Andrew Prowse 23rd May 2018	
8	CG147 Peripheral arterial disease	Identify any specific drug changes.	Catherine Henley 23rd May 2018	
9	PBR excluded drug monitoring	<ul style="list-style-type: none"> • Send JB and Peter Fry a copy of YDH format for reporting high cost drug data. • Look into why there have been some increases in costs. 	Catherine Henley Andrew Prowse 23rd May 2018	
10	Somerset Prescribing Formulary for Primary and secondary care	YDH to look at TST BNF based formulary.	Andrew Prowse 23rd May 2018	

NO.	SUBJECT	OUTSTANDING RESPONSIBILITY	ACTION LEAD	Status
11	Formulary	<p>Add Enoxaparin Becat[®] solution for injection pre-filled syringe to formulary and TLS GREEN, recommended brand prescribing.</p> <p>Esmya (ulipristal acetate) Change TLS to RED.</p> <p>Add Akynzeo to TLS RED.</p> <p>Add TA498 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma to TLS RED.</p> <p>Add TA499 Glecaprevir–pibrentasvir for treating chronic hepatitis C to TLS RED.</p> <p>Add TA500 Ceritinib for untreated ALK-positive non-small-cell lung cancer to TLS RED.</p> <p>Add TA502 Ibrutinib for treating relapsed or refractory mantle cell lymphoma to TLS RED.</p> <p>Add TA503 Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer to TLS BLACK</p> <p>Add TA504 Pirfenidone for treating idiopathic pulmonary fibrosis to TLS RED.</p> <p>Add TA505 Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma to TLS RED.</p> <p>Add TA506 Lesinurad for treating chronic hyperuricaemia in people with gout to TLS BLACK</p> <p>Add TA507 Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C to TLS RED.</p> <p>Add TA509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer to TLS RED.</p>	<p>Zoe Talbot-White Steve Moore 23rd May 2018</p>	
12	Newsletter	<ul style="list-style-type: none"> • Amended DVT Treatment Pathway • Eludxadoline and risks of pancreatitis as per MHRA DSU 	<p>Steve Moore 14th March 2018</p>	